Skip to content

The Role of Functional Epigenetic Modifications in Peri-Implantitis

The Role of Functional Epigenetic Modifications in Peri-Implantitis: A Pilot Clinical Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03753464
Enrollment
15
Registered
2018-11-27
Start date
2018-10-04
Completion date
2019-07-02
Last updated
2024-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periimplantitis

Brief summary

The aim of this pilot, exploratory, single blind clinical trial is to evaluate the epigenetic changes associated with peri-implantitis.

Detailed description

Twenty patients will be voluntarily enrolled in two groups: 10 healthy participants, and 10 participants with peri-implantitis. Periodontal and peri-implant clinical and radiographic measurements, as well as body mass index, medical and dental history will be recorded within the following timelines: at baseline (for both groups), and 6 months after baseline for the peri-implantitis group only. At baseline, gingival biopsies and blood will be harvested from: a) healthy gingival sites during either surgical removal of wisdom teeth or gingivoplasty, in the healthy group; and, b) from a peri-implantitis site during surgical treatment of peri-implantitis, and when possible, from a healthy gingival site within the same participant, in the peri-implantitis group. After harvesting of biopsies, peri-implantitis subjects will be re-evaluated 6 months after treatment. During the 6-month visit, if a second surgical treatment of peri-implantitis in the same implant treated at baseline is indicated as standard of care of the participant, a new gingiva biopsy and blood will be collected. Gingival biopsies and blood collected from each participant will be used to perform DNA methylation analysis.

Interventions

PROCEDUREGingival biopsy and blood sample collection

Gingival and blood samples will be collected.

Sponsors

NYU College of Dentistry
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

General Inclusion Criteria: * Subjects must have read, understood, and signed an informed consent form. * Subjects must be 20-90 years of age. * Subjects must be non-smokers or ex-smokers who have quit smoking for at least one year prior to enrollment in the study. * Subjects must be in good general health as assessed by the Investigator. Healthy Periodontal Subjects Inclusion Criteria: In addition to the general inclusion criteria, a healthy periodontal subject must meet all of the following criteria: • Subjects show gingival health and no history of periodontitis, as described in the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. Peri-implantitis Subjects Inclusion Criteria: In addition to the general inclusion criteria, a PIT subject must meet all of the following criteria: * Subjects with implant-supported prosthesis/es in function for at least 12 months who had at least one implant diagnosed with peri-implantitis based on the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. * Subjects must be committed to the study and the required follow-up visits. * Standard of care treatment of the diseased implant with PID will consist on open flap debridement (OFD).

Exclusion criteria

General

Design outcomes

Primary

MeasureTime frameDescription
Differences in epigenetic signatures in peri-implantitis subjects as compared to healthy subjects, in an exploratory manner. (Gingival biopsies and blood collected to perform DNA methylation analysis)6 monthsGingival and blood samples collected from healthy subjects and subjects with peri-implantitis will be used to determinate epigenetic signatures associated with peri-implantitis.
Epigenetic signatures associated with response to treatment peri-implantitis at 6 months, in an exploratory manner. (Differences in epigenetic signatures in peri-implantitis subjects as compared to healthy subjects, in an exploratory manner.6 monthsSamples collected from patients with peri-implantitis will be used to determinate epigenetic signatures associated response to treatment peri-implantitis at 6 months. (Gingival biopsies and blood collected to perform DNA methylation analysis)

Secondary

MeasureTime frameDescription
Changes in peri-implant pocket depths (PPD) (in mm) from baseline to 6 month after surgery (only peri-implantitis group).6 monthsPeri-implant pocket depths (PPD) will be assessed at baseline and 6 month after surgery.
Changes in peri-implant BOP (in percentage), from baseline to 6 month after surgery (only peri-implantitis group).6 monthsPeri-implant BOP (in percentage) will be assessed at baseline and 6 month after surgery.
Percentage of peri-implant pocket closure at to 6 month after surgery (only peri-implantitis group).6 monthsPercentage of peri-implant pocket closure will be assessed at at to 6 month after surgery.
Visual Analog Scale (VAS) will be assessed to determinate patient-reported outcome measures, at baseline and at 6 months.6 monthsA visual analog scale (VAS) will be used to evaluate patient's pain/discomfort, esthetic satisfaction, and the subjects' overall satisfaction at baseline and at 6 months.
Change in soft tissue levels (in mm) from baseline to 6 month after surgery (only peri-implantitis group).6 monthsSoft tissue levels assessed at baseline and 6 months post-surgery in implants with peri-implantitis.
Incidence of post-operative surgical site infections (only peri-implantitis group).6 monthsNumber of post-operative surgical site infections from surgery to 6 months.
Incidence of post-operative complications (only peri-implantitis group).6 monthsNumber of post-operative complications from surgery to 6 months.
Changes in peri-implant marginal bone level (in mm) from baseline to 6 month after surgery (only peri-implantitis group).6 monthsMean crestal bone level change around the implants will be determined by periapical radiographs of mesial and distal bone levels from baseline to 6 months surgery.
Oral Health Impact Profile-14 (OHIP-14) will be assessed to determinate patient-reported outcome measures, at baseline and at 6 months.6 monthsOral Health Impact Profile-14 (OHIP-14) assessed at baseline and at 6 months.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026